33.9001.51% ( -0.520 )
Delay Closed: Nov 16, 16:08:11Valuation
Current ValuationThe current P/E ratio is 26.74, within the reasonable range, cheaper than 64.45% of the time in the past 3 years, and the industry ranks 24/53, the industry Median 6.94.
26.74xP/E
HK$33.90Stock price
HK$1.27Earnings per share
26.74xP/E
Stock priceHK$33.90Earnings per shareHK$1.27
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 28.71x
- Typical range
- 22.95x–40.24x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 6.94x
010203040
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 6.94x
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
03692HKHANSOH PHARMA | 26.74x | 23.06% | HK$205.57B |
03933HKUNITED LAB | 23.42x | 55.30% | HK$14.54B |
00460HKSIHUAN PHARM | 20.33x | 322.94% | HK$7.06B |
09989HKHEPALINK | 26.68x | 18.84% | HK$5.90B |
06996HKANTENGENE-B | 28.74x | 246.19% | HK$1.77B |
03737HKZHONGZHIPHARM | 28.52x | -- | HK$578.61M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
